Thus, in addition to providing BM radiation resistance, CR or CR mimetics may provide an advantage for non-cancerous TET2 WT BM HSPCs to compete against enzyme inactive TET2 mutant HSPCs, potentially limiting aplastic anemia and/or myelodysplastic syndromes. The gene discussed is TET2; the disease is idiopathic aplastic anemia.